Trial Profile
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 15 Mar 2024 Status changed from active, no longer recruiting to completed.
- 04 Oct 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jan 2024.
- 04 Oct 2023 Planned End Date changed from 1 Oct 2023 to 1 Jul 2024.